Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688899 | 0.87 | KMT2A (0.46) | CSNK2A1CES2CES1KMT2AALDH1A1 | |
| SCHEMBL1226712 | 0.87 | KMT2A (0.46) | CSNK2A1CES2CES1KMT2AALDH1A1 | |
| SCHEMBL87104 | 0.83 | CSNK2A1 (0.61) | CSNK2A1CES2CES1KMT2AALDH1A1 | |
| SCHEMBL31011348 | 0.83 | CSNK2A1 (0.61) | CSNK2A1CES2CES1KMT2AALDH1A1 | |
| SCHEMBL16953795 | 0.82 | NFE2L2 (0.42) | CSNK2A1CES2CES1ALDH1A1CYP2A6 | |
| SCHEMBL1478262 | 0.81 | MAP2K2 (0.50) | CSNK2A1CES2CES1ALDH1A1KDM4E | |
| SCHEMBL5597538 | 0.81 | CSNK2A1 (0.59) | CSNK2A1CES2CES1KMT2AALDH1A1 | |
| SCHEMBL283993 | 0.81 | ALDH1A1 (0.52) | CSNK2A1CES2CES1KMT2AALDH1A1 | |
| SCHEMBL364307 | 0.80 | CES2 (0.68) | CES2CES1LMNA | |
| SCHEMBL29766689 | 0.80 | CES2 (0.68) | CES2CES1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151519-A2 | PPARG MODULATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. | 2024-04-25 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230330103-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2023-10-19 | — | — | US | disclosed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2020249792-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020146682-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20110172229-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
| US-7863444-B2 | 4-aminopyrrolopyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-01-04 | — | — | US | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2114867-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008107335-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20060063772-A1 | New compounds | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| US-20040132726-A1 | heterocyclic compounds, e.g., 4-(5-m-Tolyl-[1,2,4]oxadiazol-3-ylmethyl)-piperazine-1-carboxylic acid ethyl ester; treatment of mGluR5 receptor-mediated disorders, particularly neurological disorders, psychiatric disorders, acute and chronic pain. | ASTRAZENECA AB AND NPS PHARMACEUTICALS, INC. | 2004-07-08 | — | — | US | disclosed |
| EP-0772580-A1 | BENZOYL DERIVATIVES AND SYNTHESIS THEREOF | MONSANTO COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996002486-A1 | BENZOYL DERIVATIVES AND SYNTHESIS THEREOF | MONSANTO COMPANY (US) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | CSNK2A1 2607/4885CES2 2511/4885CES1 1444/4885 |
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | DLD, GCDH, DLAT | CSNK2A1 4626/4885CES2 394/4885CES1 207/4885 |
| US-20040132726-A1 | heterocyclic compounds, e.g., 4-(5-m-Tolyl-[1,2,4]oxadiazol-3-ylmethyl)-piperazine-1-carboxylic acid ethyl ester; treatment of mGluR5 receptor-mediated disorders, particularly neurological disorders, psychiatric disorders, acute and chronic pain. | GRM5, GRIK5, GRM1 | CSNK2A1 2318/4885CES2 1612/4885CES1 2175/4885 |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | CSNK2A1 2607/4885CES2 2511/4885CES1 1444/4885 |
| US-20110172229-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CSNK2A1 4280/4885CES2 1174/4885CES1 285/4885 |
| US-20060063772-A1 | New compounds | NPY4R, RPS4X, P2RX4 | CSNK2A1 1985/4885CES2 2442/4885CES1 2084/4885 |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | CSNK2A1 2607/4885CES2 2511/4885CES1 1444/4885 |
| US-20230330103-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | OXTR, AVPR1B, AVPR1A | CSNK2A1 1953/4885CES2 1696/4885CES1 2443/4885 |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | CSNK2A1 1200/4885CES2 2463/4885CES1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.